Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: colloidal anhydrous silica; calcium hydrogen phosphate; magnesium stearate; hypromellose; polysorbate 80; pregelatinised maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - quinine sulfate - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - quinine sulfate - oral tablet - 200mg

United States - English - NLM (National Library of Medicine)

mylan institutional llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 80 mg in 1 ml - sulfamethoxazole and trimethoprim injection is indicated in the treatment of pneumocystis jirovecii pneumonia in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of enteritis caused by susceptible strains of shigella flexneri and shigella sonnei in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of severe or complicated urinary tract infections in adults and pediatric patients two months of age and older due to susceptible strains of escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris when oral administration of sulfamethoxazole and trimethoprim injection is not feasible and when the organism is not susceptible to single-agent antibacterials effective in the urinary tract. to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethox

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; carnauba wax; microcrystalline cellulose; macrogol 6000; hyprolose; mannitol; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: iscover is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). iscover is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, iscover has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 351 mg (equivalent: abacavir, qty 300 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; polysorbate 80; triacetin; iron oxide yellow - ziagen (abacavir) is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and children (see clinical trials). this indication is based on surrogate endpoints in studies up to 48 weeks in duration.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet, film coated - excipient ingredients: maize starch; calcium hydrogen phosphate dihydrate; macrogol 400; carnauba wax; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - atropine sulfate - tablet - atropine sulfate 600 µg - drugs for functional gastrointestinal disorders

Kenya - English - Pharmacy and Poisons Board

guilin pharmaceutical co. ltd. no 43 qilidian road guilin 541004guangxiprchina - sulfamethoxazole and trimethoprim - tablet - sulfamethoxazole 400mg & trimethoprim 80mg - antibacterials for systemic use: combinations of

Kenya - English - Pharmacy and Poisons Board

guilin pharmaceutical co. ltd. no 43 qilidian road guilin 541004guangxiprchina - sulfamethoxazole and trimethoprim - tablet - sulfamethoxazole 800mg & trimethoprim 160mg - antibacterials for systemic use: combinations of